Triple combination of hepatic arterial infusion chemotherapy, immune checkpoint inhibitors, and tyrosine kinase inhibitors for treatment of advanced hepatocellular carcinoma: more robust evidence is still needed.
| Autor: | Rezaee-Zavareh MS; Middle East Liver Diseases Center, Tehran, Iran., Yang JD; Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Chinese clinical oncology [Chin Clin Oncol] 2024 Oct; Vol. 13 (5), pp. 77. |
| DOI: | 10.21037/cco-23-155 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|